TP53 and Miyoshi myopathy: Pre-clinical evidences obtained from administration of miRNA mimics (miR-34a [27]) and miR-192, miR-194, 215 [60]), provide promising platforms to support the concept of applying p53-activating miRNAs to MM therapeutic strategies.